

Special Issue

Radiotherapy in Melanoma

Message from the Guest Editor

Melanoma continues to steadily rise in prevalence, accounts for the majority of skin-cancer-related deaths, and remains a major public health problem. Historically, melanoma was thought to be relatively radiation therapy-resistant, and radiation therapy was thought to be of little use in treating melanoma. However, a growing body of research suggests the usefulness of especially hypo-fractionated and ablative radiation therapy in improving key outcomes. Although surgery remains the mainstay of treatment and immunotherapy has altered the treatment paradigm landscape, radiation therapy may be considered as an adjuvant, consolidative, definitive, or neoadjuvant treatment in some specific patient populations with melanoma. The purpose of this Special Issue is to examine the available data informing the use of radiation therapy in melanoma and to ultimately identify the melanoma patient populations who will derive benefit from radiation therapy.

Guest Editor

Dr. Evan Wuthrick

Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Deadline for manuscript submissions

closed (1 October 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/191514

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)